New injection shows promise for Tough-to-Treat blood cancer
NCT ID NCT07336823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new injection called JY232 in 9 people with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose. Researchers will also see if the treatment helps shrink the cancer. This is a small, early study to gather initial information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Foshan First People's Hospital
RECRUITINGFoshan, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact